Current Report Filing (8-k)
May 21 2018 - 4:20PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 17, 2018
INTELLIA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37766
|
|
36-4785571
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
40 Erie Street, Suite 130
Cambridge, Massachusetts
|
|
02139
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (857)
285-6200
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 or Rule
12b-2
of the Securities Exchange Act of 1934.
Emerging growth
company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 5.07
|
Submission of Matters to a Vote of Security Holders
|
Intellia Therapeutics, Inc. (the
Company) held its Annual Meeting of Stockholders on May 17, 2018. The following is a summary of the matters voted on at that meeting.
|
a)
|
The stockholders of the Company elected Frank Verwiel, M.D. as class II director, for a three-year term ending at the annual meeting of stockholders to be held in 2021 and until his successor has been duly elected and
qualified or until his earlier resignation or removal. The results of the stockholders vote with respect to the election of the class II director were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name
|
|
Votes
For
|
|
|
Votes
Withheld
|
|
|
Broker
Non-Votes
|
|
Frank Verwiel, M.D.
|
|
|
23,471,493
|
|
|
|
1,860,650
|
|
|
|
12,797,897
|
|
|
b)
|
The stockholders of the Company ratified the selection of Deloitte & Touche LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2018. The results
of the stockholders vote with respect to such ratification were as follows:
|
|
|
|
|
|
Votes
For
|
|
Votes
Against
|
|
Abstain
|
37,874,287
|
|
136,758
|
|
118,995
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Intellia Therapeutics, Inc.
|
|
|
|
|
Date: May 21, 2018
|
|
|
|
By:
|
|
/s/ John M. Leonard
|
|
|
|
|
|
|
John M. Leonard, M.D.
President and Chief
Executive Officer
|
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intellia Therapeutics (NASDAQ:NTLA)
Historical Stock Chart
From Apr 2023 to Apr 2024